相关实验视频
Updated: Sep 12, 2025

05:14
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
4.8K
维生素C作为抗多克索鲁比诱导心脏毒性的心脏保护剂
Hamdi Nsairat1, Zainab Lafi1, Bassam M Abualsoud1
1Pharmacological and Diagnostic Research Center, Faculty of Pharmacy Al-Ahliyya Amman University Amman Jordan.
Journal of the American Heart Association
|August 6, 2025
概括
维生素C ( Askorbic 酸) 在保护心脏免受多克索鲁比化疗损伤方面表现有前途. 研究表明,它可以降低氧化应激和炎症,从而有可能改善癌症患者的治疗结果.
科学领域:
- 心脏病学 心脏病学
- 在瘤学瘤学.
- 生物化学 生物化学
背景情况:
- 多克索鲁比是一种重要的化疗药物,但其使用受到心脏毒性的限制.
- 氧化应激和线粒体功能障碍是多克索鲁比引起的心脏损伤的关键机制.
- 维生素C (酸) 是一种抗氧化剂,具有潜在的心脏保护性质.
研究的目的:
- 审查关于维生素C在减轻多克索鲁比心脏毒性的作用的临床前和临床证据.
- 综合关于维生素C对心肌损伤标志物和心肌细胞活力影响的数据.
- 探索维生素C的心脏保护潜力的基础分子机制.
主要方法:
- 临床前 (动物模型) 和临床研究的系统审查.
- 对氧化应激,线粒体功能和炎症标志物的数据分析.
- 对心肌细胞结构完整性和活力标志物的评估.
主要成果:
- 临床前研究始终表明,维生素C可以降低氧化压力,维护线粒体功能,调节炎症.
- 动物模型表明,维生素C可以维持心肌细胞的完整性.
- 临床数据表明,维生素C在治疗中是保持心脏功能的一种安全补充,尽管结果是可变的.
结论:
- 维生素C显示出作为一种辅助疗法的潜力,以减少多克索鲁比诱导的心脏毒性.
- 需要进一步的研究来优化维生素C的剂量,时间和用于心脏保护的输送.
- 了解精确的分子机制对于临床应用至关重要.
相关概念视频
Cardiomyopathy II: Dilated Cardiomyopathy
22
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
22
Heart Failure Drugs: Inotropic Agents
724
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
724
Cardiopulmonary Resuscitation IV: Pharmacological Management
77
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
77
Cardiomyopathy V: Interprofessional Care
34
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
34
Cardiomyopathy IV: Restrictive Cardiomyopathy
31
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
31
Coronary Artery Disease IV: Preventive Measures
34
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
34

